Blog & News

ESMO Bone Cancer Youth Brochure

Sep 1, 2016 |

Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices. ESMO Bone Sarcoma Guide for Patients  

„Voices of Courage and Hope“ – Send Your Story Now!

Sep 1, 2016 |

Cancer patients know and have experienced that it can be not only helpful, but truly empowering to be part of patient community such as SPAEN. We would like to spread this inspiring and motivating feeling among other patients out there, living with…

Annual Meeting of CTOS, November 9-12, Lisbon/Portugal

Sep 1, 2016 |

NEW HORIZONS GIST 2016. Conference Report available.

Sep 1, 2016 |

Learn More About Patient Power In India

Sep 1, 2016 |

Results of 62005 study available now

Sep 1, 2016 |

            The 62005 study looked at the ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at…

New Trial CABOGIST now open

Sep 1, 2016 |

Cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib. Trial name: CABO-GIST (see more information on our study registry) Agents: Cabozantinib Phase: II Status: Open, recruiting Sponsor: European Organisation for…

7th SPAEN Conference 2016 Warsaw/Poland

Sep 1, 2016 |

 

ERNs start work March 1, 2017

Sep 1, 2016 |

    Newly established European Reference Networks (ERNs) start their work March 1, 2017 24 thematic ERNs, gathering over 900 highly specialised healthcare units from 26 countries, will begin working together on a wide range of issues. Among them the ERN for…

Interest Group Developed Sarcoma Policy Checklist

Sep 1, 2016 |

On 8th of February 2017 a rare cancer policy debate at the European Parliament took place on how to improve the policy response to rare cancers, with a focus on sarcoma. Representatives from the ​European ​Commission, ​Member States, the ​European ​Parliament,  ​industry…